UBS Group
BLTE

UBS Group’s Belite Bio BLTE Stock Holding History

UBS Group’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.6M Sell
224,989
-543,370
-71% -$83.3M ﹤0.01% 2106
2026
Q1 		$123M Buy
768,359
+639,607
+497% +$108M 0.02% 903
2025
Q4 		$20.6M Buy
128,752
+117,418
+1,036% +$13.9M ﹤0.01% 2566
2025
Q3 		$839K Buy
11,334
+8,976
+381% +$589K ﹤0.01% 5712
2025
Q2 		$136K Buy
2,358
+1,807
+328% +$110K ﹤0.01% 6987
2025
Q1 		$36.5K Sell
551
-11,656
-95% -$702K ﹤0.01% 7819
2024
Q4 		$770K Buy
12,207
+12,079
+9,437% +$796K ﹤0.01% 5517
2024
Q3 		$6K Buy
+128
New +$6.2K ﹤0.01% 8004
2024
Q1 		– Sell
-348
Closed -$15.9K – 9328
2023
Q4 		$15.9K Sell
348
-535
-61% -$20.6K ﹤0.01% 7237
2023
Q3 		$28.1K Buy
883
+583
+194% +$14.6K ﹤0.01% 6619
2023
Q2 		$4.29K Buy
300
+180
+150% +$4.09K ﹤0.01% 7550
2023
Q1 		$3.59K Sell
120
-4,097
-97% -$125K ﹤0.01% 8297
2022
Q4 		$127K Buy
+4,217
New +$124K ﹤0.01% 5879
2022
Q3 		– Sell
-683
Closed -$21K – 10340
2022
Q2 		$21K Buy
+683
New +$12.8K ﹤0.01% 6798

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's BLTE Position: Q2 2026 in Review

UBS Group reduced its Belite Bio (BLTE) stake by 71% in Q2 2026, selling an estimated $83.3M and leaving 224,989 shares worth $34.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2106.

UBS Group first reported a position in BLTE in Q2 2022 and has held it in 14 quarters since. The position peaked at $123M in Q1 2026. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • UBS Group held 224,989 shares of Belite Bio worth $34.6M as of Q2 2026.
  • UBS Group sold 543,370 Belite Bio shares in Q2 2026, an estimated $83.3M.
  • Belite Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2106 holding.
  • UBS Group first reported a position in Belite Bio in Q2 2022 and has held it in 14 quarters since.
  • UBS Group's Belite Bio position peaked at $123M in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.